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Background: Several reports have presented conflicting results regarding the association between resection
margins (RMs) and outcome after surgery for colorectal liver metastases (CLM), especially in the era of modern
chemotherapy. The purpose of this study was to evaluate the impact of RMs on overall survival (OS), time to
recurrence (TTR) and local recurrence (LR) status, particularly for patients treated with preoperative chemotherapy.
Methods: A combined retrospective (1998 to 2008) and prospective (2008 to 2010) cohort study of consecutive
patients with CLM without extrahepatic disease treated with primary resection at a medium volume centre.
Results: A total of 253 patients with known R status and 242 patients with defined margin width were included in
the study. Patients were stratified according to margin width; A: R1, <1 mm (n = 48, 19%), B: 1 to 4 mm (n = 77),
C: 5 to 9 mm (n = 46) and D: ≥10 mm (n = 71). Median time to recurrence was 12.8 months, and after five years
21.5% had no recurrence. LR (inclusive combined recurrence in other hepatic sites or extrahepatic) occurred in 40
(16.5%) cases, most frequently seen with RMs below 5 mm. Five-year OS was 42.5% in R0 and 16.1% in R1 resections
(P = 0.011). Patients were also stratified according to preoperative chemotherapy (n = 88), and the difference in
five-year OS between R0 (45.1%) and R1 (14.7%) was maintained (P = 0.037). By multiple Cox regression analysis
R1 resections tended to an adverse outcome (P = 0.067), also when adjusting for preoperative chemotherapy (P = 0.081).
Conclusions: R1 resections for colorectal liver metastases predict adverse outcome. RMs below 5 mm increased the
risk for LR and shortened the time to recurrence. Preoperative chemotherapy did not alter an adverse outcome in
R1 vs. R0 patients.
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Resection for colorectal liver metastases (CLM) has been
well established during the last three decades, with a
reported five-year survival of up to 64%, depending on
selection criteria and preoperative risk factors [1-3]. In
all intended curative cancer surgery a complete removal
of the tumor is of major importance. During the 1980s
and 1990s authors recommended ‘the 1 cm rule’ [4-7]
that probably resulted in rejection of many patients from* Correspondence: jhangelsen@gmail.com
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unless otherwise stated.CLM surgery. Several reports from the last decade have
shown that resection margins (RMs) are less important
as long as R0 status is obtained [1,8-11]. In other reports
2 mm [12] and 5 mm [13] have been suggested as suffi-
cient. Finally, some authors have even justified intended
R1 resection following great progress in pre- and post-
operative chemotherapy treatment due to an acceptable
long-term outcome [14-16].
In an advanced stage IV cancer disease like CLM most
patients are beyond curative treatment. In patients with
resectable metastases, the surgical approach and the
RMs are some of the few non-biological factors influenced
by the surgeon. The purpose of this manuscript was there-
fore to analyse in detail the local recurrence (LR) pattern,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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respect to the R1/R0 status and the magnitude of free
RMs in patients with primary resection for CLM. We also
wanted to explore whether chemotherapy altered the RMs
impact on survival.
Methods
Haukeland University Hospital is a tertiary referral centre
located in Western Norway, and serves a population of
one million. This study is a patient-based cohort with a
consecutive series of patients with CLM treated at a single
institution (1998 to 2010). Data from the period 1998 to
2008 were retrospectively recorded, and prospectively
collected from 2008 to 2010. Data were retrieved from the
patients’ medical records. All patients were prospectively
followed up with respect to survival and other characteris-
tics until November 2012. Variables analysed were TNM
stage of primary tumour, time in months between resec-
tion of primary tumor and diagnosis of liver metastases
(disease-free interval), number and size of metastases,
chemotherapy (number of cycles, response and indica-
tion), date of liver resection, complications and in-hospital
mortality, recurrence and death (perioperative, cancer-
related and other causes). RM status was obtained from
the microscopic measurements in the histological reports.
RMs <1 mm were defined as positive (R1), in accordance
with Pawlik et al. [9].
Preoperative evaluation
The selection criteria for surgery in our centre included a
sufficient remaining tumour-free liver volume (30%) with
adequate blood perfusion and bile drainage, and absence
of: a) non-resectable extrahepatic metastases, and/or b)
no disseminated disease as evaluated preoperatively. Pa-
tients with extrahepatic disease and R2 resections were
excluded from the current study. Preoperative investiga-
tions included computed tomography (CT) scan of the
chest and abdomen/pelvis, and tumour marker analysis
(CEA: carcinoembryonal antigen). In cases with an incon-
clusive CT scan, magnetic resonance imaging (MRI) of the
liver, contrast-enhanced ultrasound and 18 F-fluorodeoxy-
glucose 18(FDG)-positron emission tomography (PET)/CT
scan were performed. Each patient was discussed in a
multidisciplinary team meeting with surgeons, oncologists
and radiologists.
Chemotherapy
Preoperative chemotherapy (n = 88) was given in a peri-
operative setting (n = 43) or as a downstaging procedure
(n = 40) in patients with initially deemed unresectable
disease. Five patients developed CLM during adjuvant
treatment with chemotherapy after resection of stage III
colon cancer. We evaluated the outcome of chemother-
apy by the Response Evaluation Criteria in Solid Tumour(RECIST) version 1.1 [17]. The size of the metastases
was measured on CT scan by dedicated radiologists. All
patients in the perioperative group were offered the
FOLFOX regimen (fluorouracil, leucovorin and oxalipla-
tin) with an intended six cycles before and after surgery.
They were evaluated with CT scan after three and six
cycles. The indication for perioperative chemotherapy
has changed during the period. A total of 17 patients
were enrolled in the European Organisation for Research
and Treatment of Cancer (EORTC) multicentre study
40983 and randomised for surgery alone (n = 7), or
surgery with perioperative chemotherapy (n = 10) in the
period 2001 to 2004 [18]. After that, patients <76 years
with Eastern Cooperative Oncology Group (ECOG) per-
formance status 0 to 1 and no previous treatment with
oxaliplatin had been offered perioperative chemotherapy.
In the downstaging group, patients were treated with
several different chemotherapy regimens as listed in
Table 1. First-line treatment with the Nordic FLOX or
FLIRI regimen was most commonly used, optionally in
combination with EGFR (endothelial growth factor re-
ceptor) inhibitors or angiogenesis inhibitors.
Surgical procedures
Surgical techniques included subcostal incision, intraop-
erative ultrasonography, occasionally repeated inflow
control (the Pringle manoeuvre), and transection using
Ultracision, Kelly clamp and Cavitron Ultrasonic Surgical
Aspirator (CUSA). Throughout the period we have inten-
ded to achieve a parenchyma-sparing approach, with
wedge resections whenever possible. Formal resections
(hemihepatectomies or lobectomies) have been reserved
for metastases placed centrally or near the hepatic veins.
To increase intended complete tumour eradication, intra-
operative radiofrequency ablation, and portal vein liga-
tions/embolization with two-stage resections have been
performed. Simultaneous colorectal cancer surgery has
been reserved for healthy patients with colon cancer and
less advanced CLM. Further details are listed in Table 1.
Surveillance
Follow-up after surgery included CT scan of the chest,
abdomen and pelvis every three months for the first two
years, and thereafter every six months for the next three
years. Serum level of CEA tumour marker was obtained
every third month. We defined LR by CT scan as a new
lesion in contact with the previous resection surface.
The resected area was easily detected with CT due to the
wide use of metallic clips during the transection. The data
were based on the first detection of recurrence. Data
of recurrence were not available in four patients. Pat-
terns of recurrence were stratified according to LR,
hepatic recurrence (without LR) and extrahepatic recur-
rence. LR included patients with a) LR only, b) LR and
Table 1 Clinical characteristics and administration of
chemotherapy in 253 patients with primary resection for
colorectal liver metastases
Variable, statistics Estimate
Age in years, median (range) 66.1 (22.8, 89.2)
Gender male/female ratio 133/120
Synchronous metastasesa, n (%) 115 (45.5)
Disease-free intervalb in months, median (range) 4 (-14,131)
Resections, n 253
Hemihepatectomy/lobectomy, n (%) 117 (46.2)
Wedge/segment resections, n (%) 136 (53.8)
Simultaneous radiofrequency ablation, n (%) 12 (4.7)
Two-stage resections, n (%) 3 (1.2)
Simultaneous colorectal cancer surgery, n (%) 14 (5.5)
Extent of resection margin in mm, median (range) 4 (0-50)
Number of metastases, median (range) 2 (1, 12)
Metastases diameter in cm, median (range) 3.0 (0.2,15.0)
Bilobar metastases, n (%) 94 (37.2)
Number of resections/patient (1/2/3/4/5) 203/36/11/2/1
In-hospital mortality, n (%) 4 (1.6)
Follow-up survivors in years, median (range) 4.7 (1.9-12.9)
Chemotherapy preoperatively, n (%) 88 (34.8)
Downstaging, n (%) 40 (15.8)
Perioperativec, n (%) 43 (17.0)
Adjuvant after colon surgery, n (%) 5 (2.0)
Type of chemotherapy
FOLFOXd, n (%) 71 (81.6)
FOLFIRIe/+bevacizumab, n (%) 8/3 (9.1/3.4)
FOLFIRI + cetuximab, n (%) 1 (1.1)
FLVf, n (%) 3 (3.4)
Other combinations, n (%) 5 (5.7)
Outcome of chemotherapyg (RECIST)
Partial response, n (%) 52 (59.1)
Stable disease, n (%) 32 (36.4)
Progression, n (%) 2 (2.3)
Unknown, n (%) 2 (2.3)
Number of cycles
≤3 11 (12.5)
4-6 40 (45.4)
7-12 27 (30.7)
>12 7 (8.0)
Unknown 3 (3.4)
Table 1 Clinical characteristics and administration of
chemotherapy in 253 patients with primary resection for
colorectal liver metastases (Continued)
Chemotherapy adjuvant, n (%) 44 (17.4)
After neoadjuvant, n (%) 30 (11.9)
After downstaging, n (%) 7 (2.8)
Without preoperative chemotherapy, n (%) 7 (2.8)
aSynchronous metastases: detected <1 month after surgery of primary colorectal
tumor; bdisease-free interval: time from resection of primary colorectal tumor
to detection of hepatic metastases; call patients were offered the FOLFOX
regimen; dFOLFOX (oxaliplatin, 5-fluorouracil, leukovorin); eFOLFIRI (irinotecan,
5-fluorouracil, leukovorin); fFLV (5-fluorouracil, leukovorin); gRECIST-criteria
measured by computed tomography scan.
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comitant new extrahepatic lesions. During the follow-up,
thirteen patients died from causes other than colorectal
cancer, and six from treatment-related causes. These pa-
tients were also included in the analysis of OS, according
to the definition stated by Punt et al. [19].
Statistical analysis
Variables with possible impact on OS like RM, age, size,
number of metastases, bilobar distribution, disease-free
interval and TNM stage of primary tumour were analysed
with univariate and multivariate survival methods. The
exact chi-square (χ2) test was used for categorical vari-
ables, the t test for normally distributed variables, and the
Mann–Whitney U (MWU) test for non-normally distrib-
uted continuous variables. The Kruskal-Wallis one-way
analysis of variance test was used to compare more than
two non-normally distributed samples. Multinomial logis-
tic regression was used to evaluate LR in relation to RMs.
Survival was estimated by the Kaplan-Meier method [20]
and tested for significance with the log-rank test [21].
Multivariate analysis was performed as Cox proportional
regression [22]. Continuous predictors such as RMs were
also modelled using multiple fractional polynomial regres-
sions [23]. A P value ≤0.05 was considered significant. OS
was defined as time from resection to death irrespective of
cause, and TTR was defined as the interval between resec-
tion and the detection of a local or distant relapse [19]. All
analyses were performed using SPSS Statistics version 19
(IBM Corp., Armonk, NY, USA) and Stata 12 statistical
software (StataCorp, College Station, TX, USA). We deci-
ded to use TTR rather than disease-free survival as a
parameter in assessing recurrence patterns, since the latter
has treatment-related and non-cancer-related deaths as
endpoints, which could be misleading according to the
definition by Punt et al. [19].
Ethics
The Regional Committee of Ethics of Western Norway
Health Authority approved the study, with an exemption
to the requirement for obtaining informed consent from
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In the prospective part (2008 to 2010) patients were
enrolled through written consent.
Results
In total, 278 patients underwent 353 resections in the
13-year period. Among these, 270 patients underwent a
primary (first) liver resection. Eight patients were admitted
from other hospitals for re-resections. Fourteen patients
(5.2%) with primary resectable extrahepatic metastases
(thirteen pulmonary and one pelvic) were not included in
the current study. One patient could not complete the
second procedure of a two-stage liver resection due to
progression of disease. The R0/R1 status was not obtained
in two patients, whereas the exact resection margin (in
millimetres) could not be defined in eleven cases.
Finally, a total of 253 patients with known R status and
242 patients with a defined margin width were eligible for
further analysis. Patients were further sub-grouped accor-
ding to margin width obtained from the histological
report; A: R1, <1 mm (n = 48), B: 1 to 4 mm (n = 77), C: 5
to 9 mm (n = 46) and D: ≥10 mm (n = 71). Clinical and
pathological features are listed in Table 1. Positive micro-
scopic margins (R1) were found in 48 cases (19.0%).
Patient and tumour demographics
R1 patients had more advanced disease compared to R0
according to bilobar locations (P = 0.007, χ2-test) and
number of metastases (P = 0.099, MWU test). There was
no significant difference between R0 and R1 patients in
the TNM status of primary tumour in colon or rectum,
American Society of Anesthesiologists (ASA) score, size
of the metastases and the use of preoperative chemo-
therapy. Postoperative chemotherapy was administeredTable 2 Global recurrence and local recurrence (LR) following
according to resection margins (RMs)
Recurrence A (R1) n (%) B (1-4 mm) n (%)
LR only 7 (14.6) 3 (3.9)
LR and hepatic 3 (6.3) 3 (3.9)
LR and extrahepatic 6 (12.5) 10 (13.0)
LR (total)1 16 (33.3) 16 (20.7)
Hepatic only 8 (16.7) 15 (19.5)
Extrahepatic 13 (27.1) 31 (40.3)
Unknown 2 (4.2) 1 (1.3)
Global2 39 (81.3) 63 (81.8)
No recurrence 9 (18.8) 14 (18.2)
Total 48 (100) 77 (100)
Extrahepatic recurrence: recurrence outside the liver with or without hepatic involv
were included.
1LR (total): the sum of ‘LR only’, ‘LR and hepatic’ and ‘LR and extrahepatic’.
2Global recurrence: the sum of ‘LR (total)’, ‘hepatic only’, ‘extrahepatic’, and ‘unknowmore frequently in R1 patients (n = 12 of 48, 25.0%)
compared to R0 (n = 31 of 205, 15.1%), P = 0.016, χ2-test.
In the chemotherapy group, there was no difference in
number of R1 resections between patients with partial
response or stable disease using the RECIST criteria
(P = 0.575, χ2-test). In the perioperative and the down-
staging group a total of thirty (69.8%) and seven (17.5%)
patients, respectively, underwent postoperative chemo-
therapy (P <0.0001, χ2-test).
Patterns of recurrence
Global recurrent disease occurred in n = 175 (72.3%)
patients, whereas involvement of the resection surface was
found in 40 cases (16.5%). Further details are listed in
Table 2. We found a lower global recurrence in the groups
C and D compared to A and B. The risk for recurrence
according to RMs (A to D) was assessed with a multi-
nomial logistic regression, as detailed in Table 3. The odds
ratios for LR were significantly higher in groups A and B
relative to group D. RMs did not seem to impact hepatic
recurrence, whereas extrahepatic recurrence was more
frequent compared to no recurrence with RMs <5 mm
(0.005). A total of 21.5% of the patients were recurrence-
free after five years. TTR increased significantly (P = 0.009)
with the increasing extent of the RMs (Figure 1a), but this
difference was repealed when we omitted those patients
(n = 40) with all kinds of LR (P = 0.097). We also detected
a non-significant difference in five-year TTR between R0
(24.5%) and R1 (0%, P = 0.127). No additional benefit for
TTR was seen with RMs beyond 10 mm, where the
groups C and D were nearly equal in outcome (Figure 1a).
A total of 50 of 253 (19.8%) patients underwent a second
operation for resectable recurrence. Twenty (40.0%) of
these were due to LR after the first resection. In 27 casesn = 242 primary resections for colorectal liver metastases
Resection margins
C (5-9 mm) n (%) D (≥10 mm) n (%) All n (%)
3 (6.5) 1 (1.3) 14 (5.8)
3 (6.5) 1 (1.3) 10 (4.1)
0 (0.0) 0 (0.0) 16 (6.6)
6 (13.0) 2 (2.8) 40 (16.5)
7 (15.2) 22 (31.0) 52 (21.5)
17 (37.0) 18 (25.4) 79 (32.6)
0 (0.0) 1 (1.3) 4 (1.7)
30 (65.2) 43 (60.5) 175 (72.3)
16 (34.8) 28 (39.4) 67 (27.7)
46 (100) 71 (100) 242 (100)
ement. Statistics: P = 0.0003 (χ2 two-sided exact test) when all groups
n recurrence’.
Table 3 Results from multinomial logistic regression of
recurrence according to resection margins (RMs) in n = 242
patients with known recurrence status after primary
resection for colorectal liver metastases
Recurrence† RM OR 95% CI P value
Local R1, <1 mm 24.89 (4.77, 129.69) 0.0001
(n = 40) 1-4 mm 16.00 (3,22, 79.56) 0.001
5-9 mm 5.25 (0.95, 29.15) 0.058
≥10 mm 1.00 Reference
Hepatic only R1, <1 mm 1.13 (0.38, 3.42) 0.827
(n = 52) 1-4 mm 1.36 (0.55, 3.41) 0.508
5-9 mm 0.56 (0.20, 1.59) 0.274
≥10 mm 1.00 Reference
Extrahepatic* R1, <1 mm 2.25 (0.80, 6.33) 0.126
(n = 79) 1-4 mm 3.44 (1.45, 8.18) 0.005
5-9 mm 1.36 (0.67, 4.08) 0.276
≥10 mm 1.00 Reference
†Reference category is ‘no recurrence’ (n = 67). Unknown recurrence pattern in
n = 4 patients. *Extrahepatic: recurrence outside the liver with or without
hepatic involvement. RM, resection margins; OR, odds ratio; CI, confidence
interval.
(a)
(b)
Figure 1 Time to recurrence (a) and overall survival (b) according
to resection margins in n = 242 patients with primary resection
for colorectal liver metastases.
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whereas only three patients (6.0%) had combined intra-
and extrahepatic relapses. In patients with LR only, 11 of
14 (78.6%) patients were resected. Of the 48 patients
having a primary R1 resection, 15 (31.3%) underwent a
second operative procedure.
Overall survival
Five- and ten-year OS survival rates were 38.7% and 23.0%,
respectively, whereas median OS was 45.0 months. Five-
year OS of R0 vs. R1 was 42.5% and 16.1%, (P = 0.011,
Figure 1b), whereas median OS in R0 and R1 were 48.1
and 32.4 months, respectively. By sub-grouping according
to margin width (A to D), an increased OS was seen in the
univariate analysis (P = 0.035, see Figure 1b). However,
there was no extra benefit when the RMs exceeded 10 mm
(group C vs. D). Patients were also stratified according to
preoperative chemotherapy (n = 88), and the difference
in five-year OS between R0 and R1 was maintained
(P = 0.037). In the perioperative group (n = 43), a non-
significant difference (P = 0.502) in five-year OS was seen
between R1 (34.3%) and R0 (54.2%). In the downstaging
group (n = 40), the five-year OS was 40.2% for the R0
cases vs. none survivors in the R1 group (P = 0.017).
Patients with initially unresectable metastases had more
extensive disease evaluated as the average number of
metastases (3.6) compared to the perioperative (2.5) and
the surgery alone group (2.3), using Kruskal-Wallis test
(P = 0.002). Positive RMs also predicted a borderline sig-
nificant adverse outcome in the Cox proportional hazards
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metastases, size of the metastases and repeated resections
(Table 4). When using the RM sub-groups (A to D) in the
Cox model (P = 0.111) and the RMs as a continuous vari-
able (P = 0.099), significance was not reached. We neither
found any substantial differences in OS with a cut-off
margin of 5 mm (P = 0.194). We also applied multiple
fractional polynomials in the Cox regression model with-
out identifying any non-linear relationships between RMs
and OS. When adjusting for patients offered preoperative
chemotherapy, multivariate analyses revealed RMs still to
be a borderline significant factor predicting adverse OS
(P = 0.081). However, in contrast to the rest, there was an
adverse effect on OS of R1 vs. R0 in the downstaging
group (test of interaction P = 0.020), adjusting for the
same variables as listed in Table 4. No such effect was
evident in the perioperative group.
Finally, we conducted survival calculations according
to the site of recurrence and the involvement of LR
independently of RMs. We could not reveal any differ-
ence in five-year OS between LR (total), hepatic-only
and extrahepatic recurrence (P = 0.947). Patients with LR
only proved a better five-year OS compared to patients
with recurrence at other sites (35.9% vs. 25.4%, P = 0.048).Table 4 Results from Cox regression analysis of resection mar
patients after primary resection for colorectal liver metastase
Univariate
Variable n HR 95% CI
Age/10 y 253 1.32 (1.12, 1.54)
DFI, months 253 0.91 (0.80, 1,03)
Number of metastases 253 1.19 (1.10, 1.28)
Metastasis diam, cm 242 1.11 (1.03, 1.19)
RM status R0 205 1.00 Reference
R1 48 1.69 (1.14, 2.51)
T stage
T2 25 1.00 Reference
T3 180 1.10 (0.65, 1.87)
T4 34 1.11 (0.57, 2.19)
N stage
N0 91 1.00 Reference
N1 103 1.19 (0.83, 1.72)
N2 51 1.27 (0.81, 1.98)
ASA score 253 1.62 (1.20, 2.19)
Bilobar No 159 1.00 Reference
Yes 94 1.38 (1.01, 1.89)
Re-resections 0.78 (0.60, 1.01)
HR, hazard ratio; CI, confidence interval; DFI, disease-free interval (time between res
hepatic metastases); RM, resection margin; T and N stage, analysis of primary tumo
T-stage n = 14, unknown N-stage: n = 8, unknown diameter of metastases: n =11.Within the latter group we neither found any substantial
differences in OS (P = 0.130).
Discussion
The main finding in this study was that positive RMs
influenced overall survival after resection for CLM. LR
occurred more frequently and TTR was shorter in
RMs <5 mm. Following preoperative chemotherapy,
negative margins were still a prerequisite for achieving an
improved survival.
Our study demonstrated that positive margins were
related to a more dismal prognosis. This is consistent
with the majority of other comparable reports [1,9,24-26].
Even with a consensus on obtaining free margins after
liver resections there are still conflicting results about the
sufficient magnitude of the RMs and its impact on recur-
rence and survival. Several studies have shown that local
recurrence and survival were independent of the extent of
the free margins [8,9,11,27]. In addition to the benefit of
R0, we found an increasing OS and TTR in patients with
RMs >5 mm (Figures 1a and b). No additional advantage
was found for free RMs beyond this limit. In the report
from Nuzzo et al. a RM ≤5 mm was associated with a
greater risk of LR, as well as reduced disease-free survivalgins and other factors affecting overall survival in 253
s
Overall survival
Multivariate
P HR 95% CI P
<0.001 1.29 (1.08, 1.54) 0.005
0.122 0.91 (0.79, 1.05) 0.187
<0.001 1.31 (1.17, 1.45) <0.001
0.006 1.09 (1.02, 1.18) 0.023
1.00 Reference
0.014 1.53 (0.98, 2.39) 0.067
0.931 0.897
1.00 Reference
0.99 (0.54, 1.81)
0.88 (0.40, 1.90)
0.506 0.229
1.00 Reference
1.32 (0.88, 1.98)
1.49 (0.92, 2.42)
0.002 1.61 (1.13, 2.29) 0.009
1.00 Reference
0.048 1.22 (0.80, 1.86) 0.353
0.045 0.71 (0.52, 0.97) 0.016
ection of the primary tumor in the colon or rectum and the detection of
r in colon or rectum; ASA, American Society of Anesthesiologists. Unknown
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strated that a RM >1 mm improved OS. However, a mar-
gin beyond 1 mm did not yield any detectable advantage
in survival [28]. In a large series of 2,715 prospective
collected patients Hamady et al. stated that 1 mm free
margin was sufficient to obtain a five-year DFS of 33%. An
extra margin width did not provide DFS advantage in this
study [29]. Konopke et al. showed that even though the
size of the RMs did not affect overall survival, a resection
margin below 3 mm increased hepatic and overall recur-
rence [30]. Wray et al. found that RM <1 cm was a power-
ful factor in increasing the risk for local and distant
recurrence as well as DFS [31]. The result was, however,
not confirmed in a multivariate setting when only R0 cases
were included.
Several studies have through genetic techniques detec-
ted tumour DNA up to 4 mm from the tumour border,
and thereby determining a rational basis for the extent of
surgical excision [12,32-34]. We also demonstrated that
RMs plays a key role in the development of LR inde-
pendently of recurrence in other sites of the liver and/or
extrahepatic (Tables 2 and 3) using multinomic logistic
regression. Furthermore, no correlation was detected be-
tween RMs and intra- or extrahepatic relapse without LR
involvement (Table 3). Surprisingly, we detected an in-
creased risk for extrahepatic recurrence in patients with
less than 5 mm free margins. We have no plausible
explanation for this finding, and the results may suggest
that RMs might be surrogates of the extent of the disease.
This is also visualized through a fairly high level of recur-
rence (89.4%) in the group B (1 to 4 mm, Figure 1), as
40.3% of these patients had extrahepatic recurrence
(Table 2). We hypothesise that intra- or extrahepatic
relapse (without LR involvement) is based on progression
of preoperatively non-detectable micro-metastases and
not the impact of RMs. Unlike our report, de Haas et al.
found that R1 was associated with intrahepatic recurrence,
whereas no difference in surgical margin recurrence was
seen between R0 and R1 [14]. Likewise, in the multi-
institutional study of 1,669 patients by de Jong et al., R1
resection was associated with intrahepatic recurrence,
whereas extrahepatic disease developed independently of
margin status [3].
In the study by Are et al. the RMs were analysed as a
continuous variable [35]. They found no difference in
survival between positive margins and sub-centimetre
resections (P = 0.31) in the multivariate analysis, whereas
patients with RM >1 cm had a significantly improved
outcome. Nevertheless, the authors observed a favourable
survival in sub-centimetre R0 resections, and they con-
cluded that these patients should not be denied hepatic
resections.
In some published articles, with initially marginally or
non-resectable CLM receiving preoperative chemotherapy,the important role of free margins were found to be less
important [14-16]. In the current study, we found an im-
proved OS for R0 vs. R1 in patients receiving preoperative
chemotherapy. Our data indicates that R0 resections
should be strived for in these patients. This finding also
corresponds with recently published studies [36,37]. In
patients with initially unresectable metastases successfully
treated with chemotherapy, positive margins predicted in
the univariate model an adverse outcome (P = 0.017), but
this finding was not evident in resectable patients offered
perioperative chemotherapy (P = 0.502). In the multi-
variate analysis this difference was confirmed. In the first
group, postoperative chemotherapy was administered
more rarely (17.5%) compared with the latter group
(69.8%). In other settings like stage III colon cancer, adju-
vant chemotherapy regimens have proved to expose and
reduce the recurrence rates [38,39]. We hypothesise the
same mechanism in R1 patients, where adjuvant chemo-
therapy may suppress any remaining metastatic disease,
leading to an increase in TTR and OS. This resembles the
trial by Tranchart et al. [37].
An exact measurement of RMs is impeded by the
application of surgical devices such as the ultrasonic
aspirator, harmonic scalpel, and Kelly clamp-crushing
technique, which removes a small rim of liver tissue dur-
ing the transection. An overestimation of R1 cases might
be the consequence [9,14]. Likewise, the invasive irregu-
lar growth pattern in liver metastases, combined with a
rough transection surface, makes the histological exam-
ination less reliable in narrow margins. The increasing
use of chemotherapy may also complicate the measure-
ment of RMs due to a more irregular surface, as reported
by Ng et al. [34].
Several studies have demonstrated an effect of R1
resections on OS in univariate analyses, but have not
confirmed this finding in a multivariate setting [9,13,35].
This result has led to a discussion whether R status is a
surrogate of other biologic factors such as size, number,
growth patterns and distribution of the metastases, rather
than an independent predictor for adverse outcome. In
the current trial R1 was of borderline significance in the
multivariate analysis (P = 0.067). However, a more advan-
ced disease in patients undergoing R1 vs. R0 resection is
reflected by a higher incidence of bilobar distribution and
number of metastases. This is consistent with other recog-
nized reports [9,14,35]. The advancement of disease
reflected in number and size of metastases appears to have
greater impact on survival than RMs. Based on our find-
ings we advocate that R0 should be performed despite no
clear significance in the Cox model. We also assume with
a larger number of patients in the cohort, the significance
might be obtained.
We reported a rather high incidence of LR (total) and
global recurrence of 40 (16.5%), and 175 (72.3%) patients,
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[9,12,13]. The RMs (groups A to D) did not influence the
TTR when patients with LR (total) were excluded from
the analysis (P = 0.097). A similar finding in TTR was
evident between R1/R0 (P = 0.403). However, we could
neither detect any worse OS in patients with LR (total)
compared with patients with recurrence at other sites. A
fairly high proportion of patients with LR were offered
repeated resections with curative intent. In patients with
LR only, 78.6% underwent a second resection, following
better OS compared with recurrence in other sites. We
could not obtain a different OS among patients with re-
lapse in other localisations. Despite a high recurrence rate,
we have obtained a five-year OS of nearly 40% and a me-
dian OS of 45 months. We assume an aggressive multi-
modal treatment and with repeated resections in patients
with advanced disease and marginally resectable metasta-
ses may be justified despite the high number of relapse
[14]. Based on this, patients with suspected narrow RMs
should not be excluded from resection for colorectal liver
metastases.
Conclusions
A positive resection margin predicted adverse OS after
resection for colorectal liver metastases. Likewise, local
recurrence and time to recurrence were influenced by
positive margins. In addition, an increasing survival rate,
a reduced recurrence (local and global) rate and a longer
time to recurrence were seen in patients with RM >5 mm,
but could not be verified beyond this extent. In an era
with expanding use of chemotherapy, our study supports
that R0 resections are still important in order to obtain
the best outcome in patients treated with resection for
colorectal liver metastases.
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